Travere Therapeutics
TVTX
174 hedge funds and large institutions have $736M invested in Travere Therapeutics in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 72 increasing their positions, 50 reducing their positions, and 28 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 50
9% more capital invested
Capital invested by funds: $677M → $736M (+$58.9M)
7% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 28
0.34% more ownership
Funds ownership: 115.35% → 115.68% (+0.34%)
1% less funds holding
Funds holding: 175 → 174 (-1)
52% less call options, than puts
Call options by funds: $1.81M | Put options by funds: $3.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$13.4M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$8.6M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$7.12M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.15M |
| 5 |
Millennium Management
New York
|
+$5.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$20.9M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.8M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$8.49M |
| 4 |
Renaissance Technologies
New York
|
-$4.43M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.71M |
TVTX Hedge Fund Activity: Q2 2024 in Review
174 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2024, worth a combined $736M — up 8.7% from $677M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new TVTX positions and 28 closed out — a net gain of 2 holders — while 72 added to existing stakes and 50 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $13.4M. The largest seller was State Street, cutting an estimated $20.9M.
- 174 institutional investors held Travere Therapeutics (TVTX) as of Q2 2024, down from 175 in Q1 2024.
- Funds reported $736M of Travere Therapeutics stock for Q2 2024, up 8.7% quarter-over-quarter.
- 30 funds opened new Travere Therapeutics positions in Q2 2024 and 28 closed out, a net change of +2 holders.
- The largest Travere Therapeutics buyer in Q2 2024 was Assenagon Asset Management, an estimated $13.4M added.
- The largest Travere Therapeutics seller in Q2 2024 was State Street, an estimated $20.9M sold.
Based on aggregated 13F filings for Q2 2024.